GlassScriptPhysician profile
Riyad Seervai
NPI 1235872615
$9,928.99
in general payments reported to CMS, 2019-2025
19 companies · $5,840 in 2025
The $5,840 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $549 · 2024: $3,541 · 2025: $5,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,569 · Travel and Lodging: $1,142 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,568.52 |
| Travel and Lodging | $1,141.86 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $218.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,955.96 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $1,395.02 | 2024-2025 | |
| Genzyme Corporation | $1,021.15 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $942.08 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $796.82 | 2023-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $596.62 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $561.02 | 2024 | Siliq, Jublia, Cabtreo |
| Janssen Biotech, INC. | $547.76 | 2024-2025 | Tremfya |
| Ucb, INC. | $415.14 | 2024-2025 | Bimzelx |
| Amgen INC. | $346.85 | 2024-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $312.68 | 2023-2024 | Vtama |
| Incyte Corporation | $305.55 | 2024-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $304.79 | 2024 | |
| Lilly USA, LLC | $117.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.41 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $81.81 | 2024 | |
| Pfizer INC. | $61.60 | 2025 | |
| Almirall LLC | $45.74 | 2025 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $22.21 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riyad Seervai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.